Cybin Gets UK Green Light for Psychedelic Depression Trial
Ticker: HELP · Form: 6-K · Filed: Jul 17, 2025 · CIK: 1833141
| Field | Detail |
|---|---|
| Company | Cybin INC. (HELP) |
| Form Type | 6-K |
| Filed Date | Jul 17, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial, regulatory-approval, pharmaceuticals, mental-health
TL;DR
Cybin's psychedelic drug CYB003 cleared for UK Phase 2b depression trial by MHRA.
AI Summary
Cybin Inc. announced on July 17, 2025, that it has received a Clinical Trial Authorisation (CTA) from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its Phase 2b study of CYB003. This study will evaluate the safety and efficacy of CYB003, an investigational psychedelic therapy, in adults with major depressive disorder (MDD). The trial is expected to enroll approximately 120 participants across multiple sites in the UK.
Why It Matters
This MHRA approval is a significant step for Cybin, allowing them to advance their novel psychedelic therapy for depression into a crucial late-stage clinical trial in a major market.
Risk Assessment
Risk Level: medium — The company is in the clinical trial phase for an investigational drug, which carries inherent risks related to trial success and regulatory approval.
Key Numbers
- Phase 2b — Clinical Trial Phase (Study for CYB003 in MDD)
- 120 — Participants (Expected enrollment for the Phase 2b study)
Key Players & Entities
- Cybin Inc. (company) — Registrant
- UK MHRA (company) — Regulatory Agency
- CYB003 (drug) — Investigational psychedelic therapy
- July 17, 2025 (date) — Announcement Date
- Doug Drysdale (person) — CEO
- major depressive disorder (MDD) (condition) — Indication for CYB003
FAQ
What is the primary purpose of the Phase 2b study for CYB003?
The Phase 2b study aims to evaluate the safety and efficacy of CYB003 in adults diagnosed with major depressive disorder (MDD).
Which regulatory body granted the Clinical Trial Authorisation (CTA)?
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) granted the CTA.
When was the news release regarding the MHRA approval filed?
The news release was dated July 17, 2025.
Where will the Phase 2b study for CYB003 be conducted?
The study will be conducted across multiple sites in the UK.
Who signed the Form 6-K report on behalf of Cybin Inc.?
Doug Drysdale, Chief Executive Officer, signed the report.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 17, 2025 by Doug Drysdale regarding CYBIN INC. (HELP).